drugset / Trial / NCT01806376
A Phase I Study of Subutinib Maleate Capsules on Toleration and Pharmacokinetics
Phase 1
Unknown
20 enrolled
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Fudan University · collab
NaSingle-groupOpen-labelPrevention
Summary
1. purpose: to explore the maximum tolerated dose, dose-limiting toxicity of oral Subutinib Maleate capsules and rational dosage regimen for phase Ⅱ study 2. Experimental Design： A phase Ⅰ study of single-center 3. Test drug: Subutinib Maleate capsules 4. Sample size≥20
Timeline
- Start
- 2013-03
- Primary completion
- 2014-09
- Completion
- 2014-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Subutinib | Unknown | — | Oral |